Fig. 2: Overall survival (OS) of patients eligible or not to adjuvant abemaciclib according to monarchE inclusion criteria. | npj Breast Cancer

Fig. 2: Overall survival (OS) of patients eligible or not to adjuvant abemaciclib according to monarchE inclusion criteria.

From: Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib

Fig. 2

A Kaplan-Meier estimates for overall survival (OS) according to eligibility (red curve) or non-eligibility (blue curve) for adjuvant abemaciclib (according to the monarchE risk-based inclusion criteria). B Kaplan-Meier estimates for overall survival (OS) according to eligibility or not for adjuvant abemaciclib (according to the monarchE risk-based inclusion criteria), and axillary lymph node status: patients eligible for adjuvant abemaciclib with ≥4N+ (red curve), patients eligible for adjuvant abemaciclib with 1-3N+ (blue curve), patients not eligible for adjuvant abemaciclib with 1-3N+ (brown curve), and patients not eligible for adjuvant abemaciclib without node involvement (green curve). Median OS, median follow-up, number of events (deaths), and OS at 2, 3, 5, and 10 years are shown in the table below each survival curve.

Back to article page